OPCH: Growth in acute and specialty therapies, portfolio diversification, and new rare drugs drive momentum
Momentum has stabilized with growth in acute and specialty therapies, supported by a diversified portfolio and strong hospital partnerships. Biosimilar competition and new rare therapies are expected to drive future growth, while regulatory changes and capital allocation remain focused on expanding…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.